Analeah Heidt, Ph.D.

Analeah leads translational research at Inhibrx and is responsible for non-clinical research in support of multiple IND filings annually. Prior to joining Inhibrx she spent ten years at Novartis in biologics drug discovery in multiple roles from oncology target validation through candidate optimization for varied therapeutic modalities, including antibody drug conjugates and immune activating agents. Analeah received her Ph.D. from the University of California, San Francisco in biochemistry and molecular biology and completed her postdoctoral research at the Genomics Institute for the Novartis Research Foundation.